Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events

Advances in Therapy

Volumn 28, Issue 6, 2011, Pages 473-482

  Guthrie, Robert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

adverse events; antiplatelet; bleeding; secondary stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; TICLOPIDINE;

ABDOMINAL PAIN; ANTICOAGULANT THERAPY; BEDTIME DOSAGE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTENDED DRUG RELEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STROKE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VOMITING;

ASPIRIN; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; HEADACHE; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK FACTORS; STROKE; TICLOPIDINE;

EID: 79958257506     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0026-0     Document Type: Review

References (29)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-276.
3. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276-2293.
4. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology. 2005;64:817-820. (Pubitemid 40316318)
5. Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2006;60:301-313. (Pubitemid 44523332)
6. Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition. Stroke. 2004;35:1925-1929. (Pubitemid 38971877)
7. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284:2901-2906.
8. Lovett JK, Dennis MS, Sandercock PA, Bamford J, Warlow CP, Rothwell PM. Very early risk of stroke after a first transient ischemic attack. Stroke. 2003;34:e138-140.
9. Fonarow GC, Smith EE, Reeves MJ, et al. Hospital-level variation in mortality and rehospitalization for Medicare beneficiaries with acute ischemic stroke. Stroke. 2011;42:159-166.
10. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(Suppl. 6):630S-669S.
11. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13. (Pubitemid 26402780)
12. [No authors listed.] A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med. 1991;325:1261-1266.
13. [No authors listed.] Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet. 1991;338:1345-1349.
14. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044-1054.
15. [No authors listed.] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
16. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
17. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
18. The ESPIRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPIRIT): a randomised controlled trial. Lancet. 2006;367:1665-1673.
19. Aggrenox (aspirin/extended-release dipyridamole) capsules. Prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2009.
20. Plavix (clopidogrel bisulfate). Prescribing information. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2010.
21. Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W. Dipyridamole bioavailability in subjects with reduced gastric acidity. J Clin Pharmacol. 2005;45:845-850. (Pubitemid 40875337)
22. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-1251.
23. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257:399-414. (Pubitemid 40604544)
24. Rahman M, Beattie J. Peri-operative medication in patients with cardiovascular disease. Pharm J. 2004;272:352-354. (Pubitemid 38425994)
25. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(Suppl. 6):299S-339S.
26. Patrano, Carlo, Baigent C, Hirsh, Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(Suppl. 6):199S-233S.
27. Theis JG, Deichsel G, Marshall S. Rapid development of tolerance to dipyridamole-associated headaches. Br J Clin Pharmacol. 1999;48:750-755. (Pubitemid 29520600)
28. Chang YJ, Ryu SJ, Lee TH. Dose titration to reduce dipyridamole-related headache. Cerebrovasc Dis. 2006;22:258-262.
29. Bennett CJ, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777. (Pubitemid 30390236)